AU2018221881B2 - Formulations of cannabinoids for the treatment of acne - Google Patents

Formulations of cannabinoids for the treatment of acne Download PDF

Info

Publication number
AU2018221881B2
AU2018221881B2 AU2018221881A AU2018221881A AU2018221881B2 AU 2018221881 B2 AU2018221881 B2 AU 2018221881B2 AU 2018221881 A AU2018221881 A AU 2018221881A AU 2018221881 A AU2018221881 A AU 2018221881A AU 2018221881 B2 AU2018221881 B2 AU 2018221881B2
Authority
AU
Australia
Prior art keywords
cbd
day
cannabidiol
skin
acne
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018221881A
Other languages
English (en)
Other versions
AU2018221881A1 (en
Inventor
Matthew CALLAHAN
Eugene Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Inc
Original Assignee
Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900493A external-priority patent/AU2017900493A0/en
Application filed by Botanix Pharmaceuticals Ltd, Botanix Pharmaceuticals Inc filed Critical Botanix Pharmaceuticals Ltd
Priority claimed from PCT/AU2018/050045 external-priority patent/WO2018148786A1/en
Publication of AU2018221881A1 publication Critical patent/AU2018221881A1/en
Application granted granted Critical
Publication of AU2018221881B2 publication Critical patent/AU2018221881B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
AU2018221881A 2017-02-15 2018-01-24 Formulations of cannabinoids for the treatment of acne Ceased AU2018221881B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762459313P 2017-02-15 2017-02-15
US62/459,313 2017-02-15
AU2017900493 2017-02-15
AU2017900493A AU2017900493A0 (en) 2017-02-15 Formulations of Cannabinoids for the Treatment of Acne
PCT/AU2018/050045 WO2018148786A1 (en) 2017-02-15 2018-01-24 Formulations of cannabinoids for the treatment of acne

Publications (2)

Publication Number Publication Date
AU2018221881A1 AU2018221881A1 (en) 2019-09-05
AU2018221881B2 true AU2018221881B2 (en) 2023-09-14

Family

ID=67766784

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018221881A Ceased AU2018221881B2 (en) 2017-02-15 2018-01-24 Formulations of cannabinoids for the treatment of acne

Country Status (9)

Country Link
US (1) US20220323401A1 (enExample)
EP (1) EP3582770A4 (enExample)
JP (2) JP2020508992A (enExample)
CN (1) CN110769819A (enExample)
AU (1) AU2018221881B2 (enExample)
BR (1) BR112019017049A2 (enExample)
CA (1) CA3053503C (enExample)
IL (1) IL268728B2 (enExample)
NZ (1) NZ756307A (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020508992A (ja) * 2017-02-15 2020-03-26 ボタニクス ファーマシューティカルズ リミテッド ざ瘡の処置のためのカンナビノイドの製剤
WO2021173800A1 (en) * 2020-02-25 2021-09-02 Advanced Animal Diagnostics, Inc. Methods and compositions for identifiying a survivability index for an animal
CN114073687A (zh) * 2020-08-21 2022-02-22 四川大学华西医院 大麻二酚在制备防治玫瑰痤疮的药物中的用途
CN113372196B (zh) * 2021-07-02 2022-09-30 江南大学 8,9-二氢大麻二酚及其合成方法与应用
JP7736309B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機
JP7736308B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機
JP7736306B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機
JP7736310B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002065997A1 (en) * 2001-02-21 2002-08-29 Unilever Plc Antiperspirant or deodorant compositions
WO2003007901A1 (en) * 2001-07-18 2003-01-30 Unilever Plc Hair and/or scalp treatment compositions
WO2008024408A2 (en) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2015161165A1 (en) * 2014-04-18 2015-10-22 Mary's Medicinals LLC Transdermal cannabinoid patch
US20160374958A1 (en) * 2015-06-23 2016-12-29 Axim Biotechnologies, Inc. Anti-microbial composition comprising cannabinoids

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009090495A2 (en) * 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
WO2010127033A1 (en) * 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
EP2444081B1 (en) * 2010-10-19 2015-04-08 Parenteral, A.S. A composition for the treatment of inflammatory diseases comprising boswellic acids and cannabidiol
US8758826B2 (en) * 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
US20130184354A1 (en) * 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
NZ707855A (en) * 2012-11-06 2018-11-30 Rochal Ind Llc Delivery of biologically-active agents using volatile, hydrophobic solvents
WO2014116653A1 (en) * 2013-01-22 2014-07-31 Coty Inc. Topical formulations and methods for the use thereof
EP3265081A4 (en) * 2015-03-02 2018-11-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
JP2020508992A (ja) * 2017-02-15 2020-03-26 ボタニクス ファーマシューティカルズ リミテッド ざ瘡の処置のためのカンナビノイドの製剤
AU2018221880B2 (en) * 2017-02-15 2023-08-17 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002065997A1 (en) * 2001-02-21 2002-08-29 Unilever Plc Antiperspirant or deodorant compositions
WO2003007901A1 (en) * 2001-07-18 2003-01-30 Unilever Plc Hair and/or scalp treatment compositions
WO2008024408A2 (en) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2015161165A1 (en) * 2014-04-18 2015-10-22 Mary's Medicinals LLC Transdermal cannabinoid patch
US20160374958A1 (en) * 2015-06-23 2016-12-29 Axim Biotechnologies, Inc. Anti-microbial composition comprising cannabinoids

Also Published As

Publication number Publication date
US20220323401A1 (en) 2022-10-13
AU2018221881A1 (en) 2019-09-05
JP2022185150A (ja) 2022-12-13
EP3582770A4 (en) 2020-11-18
BR112019017049A2 (pt) 2020-04-14
CA3053503C (en) 2024-04-23
NZ756307A (en) 2023-01-27
IL268728B2 (en) 2024-09-01
CA3053503A1 (en) 2018-08-23
IL268728B1 (en) 2024-05-01
IL268728A (en) 2019-10-31
EP3582770A1 (en) 2019-12-25
CN110769819A (zh) 2020-02-07
JP2020508992A (ja) 2020-03-26

Similar Documents

Publication Publication Date Title
AU2018221881B2 (en) Formulations of cannabinoids for the treatment of acne
AU2018221880B2 (en) Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
WO2018148786A1 (en) Formulations of cannabinoids for the treatment of acne
WO2018148787A1 (en) Formulations of cannabinoids for the treatment of psoriasis
WO2018148785A1 (en) Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
WO2019144190A1 (en) Cannabinoid dosing regime for dermatitis and inflammatory skin conditions
JP7561252B2 (ja) ざ瘡のためのカンナビノイド投薬レジメン
US20220313621A1 (en) Formulations of cannabinoids for the treatment of psoriasis
US20190224137A1 (en) Cannabinoid Dosing Regime for Acne
US20220331269A1 (en) Compositions for treating acne
WO2018148795A1 (en) Compositions for treating acne

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired